Core Viewpoint - The article discusses the significance of synonymous mutations in genetic research, particularly their role in cucumber domestication through epitranscriptomic regulation, challenging traditional views on these mutations [2][3]. Group 1: Research Findings - The study published in the journal Cell demonstrates that synonymous mutations can regulate important traits in cucumber by altering m6A modifications and mRNA structural conformations [2][3]. - The research identifies two closely linked genes, YTH1 and ACS2, that interact epistatically to influence cucumber fruit length [5][9]. - A specific synonymous mutation, 1287C>T in the ACS2 gene, is identified as a pathogenic mutation that disrupts m6A methylation and alters RNA structure, leading to changes in fruit length [6][9]. Group 2: Genetic Mechanisms - The YTH1 gene encodes an m6A reader protein, while the ACS2 gene encodes a rate-limiting enzyme for ethylene synthesis in plants, both of which are crucial for cucumber domestication [5][9]. - The study reveals that the wild-type cucumber's ACS2 1287C leads to m6A modification and a loose RNA structure, while the cultivated cucumber's ACS2 1287T results in a compact RNA structure, affecting protein levels and fruit length [6][9].

Core Viewpoint - The article discusses an innovative method for chemically recycling mixed plastic waste into valuable chemical products, addressing the environmental challenges posed by plastic waste [2][3]. Group 1: Research Overview - The research, published in Nature, presents a strategy to convert eight common types of plastic waste into their original chemical components or other valuable compounds [3][10]. - The method focuses on identifying functional groups in mixed plastic waste to facilitate the separation and conversion of these materials into useful products [5][8]. Group 2: Methodology - The research team developed a solid-state NMR method to accurately identify the types of plastics present in the mixed waste, which is crucial for the subsequent processing steps [5][6]. - By using selective solvents, the team was able to dissolve and separate specific plastics from the mixed waste, followed by catalytic processes to convert these plastics into valuable products [6][7]. Group 3: Results and Innovations - The study successfully demonstrated the feasibility of the proposed strategy using a real-life plastic mixture, yielding various chemical substances such as benzoic acid, plasticizers, and hydrocarbons [7][8]. - The key innovation lies in the universal strategy designed to tackle the challenge of chemical recycling of mixed plastics, allowing for adjustments in chemical steps based on the initial identification of major components [8][10].

Core Viewpoint - Google’s subsidiary Calico Life Sciences has entered into a nearly $600 million biopharmaceutical deal with Mabwell to acquire rights to a research therapy targeting Interleukin-11 (IL-11), including a clinical-stage monoclonal antibody 9MW3811 for age-related diseases [2][3]. Group 1: Deal Details - Mabwell has explored the therapeutic potential of 9MW3811 in age-related diseases during preclinical research, completing Phase 1 clinical studies in China and Australia, showing promise for treating idiopathic pulmonary fibrosis, and has received approval to conduct Phase 1 clinical studies in the United States [3]. - Under the licensing agreement, Mabwell grants Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 outside Greater China. Calico will pay an upfront non-refundable fee of $25 million, with potential additional payments of up to $571 million based on milestones, as well as tiered royalties based on net sales of the licensed product [3]. Group 2: Company Background - Calico was co-founded by Alphabet, Google's parent company, and industry leader Dr. Arthur Levinson, with the aim of understanding the biological principles of aging to help develop interventions that extend and improve lifespan. Calico has established partnerships with several organizations, including AbbVie and the Broad Institute of MIT and Harvard [3]. - Mabwell is an innovative biopharmaceutical company with a full industry chain layout, focusing on tumors and age-related diseases, covering treatment areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and infections [4].

Core Viewpoint - AbbVie is making a significant move into the in vivo CAR-T market by acquiring Capstan Therapeutics for $2.1 billion in cash, aiming to integrate a candidate therapy for autoimmune diseases, CPTX2309, which is currently in Phase 1 clinical trials [2][9]. Group 1: Capstan Therapeutics Overview - Capstan Therapeutics, founded in early 2022, focuses on in vivo reprogramming of T cells to address manufacturing and scalability challenges in CAR-T therapies, allowing patients to avoid lymphocyte-depleting chemotherapy prior to treatment [3][9]. - The company has raised $340 million from various pharmaceutical giants and venture capital firms, with a founding team that includes pioneers in CAR-T cell therapy and mRNA technology [9]. Group 2: In Vivo CAR-T Technology - The in vivo CAR-T technology was developed based on a research paper published by researchers at the University of Pennsylvania in January 2022, which introduced a method to generate CAR-T cells in situ using lipid nanoparticles to deliver mRNA [6][12]. - This innovative approach, similar to mRNA vaccines, aims to simplify the CAR-T cell production process, addressing issues such as complexity, time, and high costs associated with traditional methods [7][14]. Group 3: Clinical Development and Applications - Capstan's lead product, CPTX2309, is currently in Phase 1 clinical trials for treating B cell-mediated autoimmune diseases, with promising preclinical results demonstrated in animal models [11][19]. - The therapy utilizes targeted lipid nanoparticles to deliver mRNA encoding CD19 CAR to CD8+ T cells, effectively generating CAR-T cells that can eliminate autoreactive B cells while allowing for the regeneration of healthy B cells [19][20]. Group 4: Market Context and Potential - Since 2017, the FDA has approved six CAR-T therapies for various B cell malignancies, with hundreds more in clinical trials globally, highlighting the growing interest and potential in the CAR-T market despite existing challenges [14][15]. - Recent advancements in CAR-T therapies for autoimmune diseases have shown significant clinical benefits, indicating a promising avenue for future treatments [15].

Core Viewpoint - The article discusses a groundbreaking study that successfully developed highly vascularized lung and gut organoids using human induced pluripotent stem cells (iPSCs), addressing the limitations of traditional organoid models that lack functional vascular networks and organ-specific characteristics [2][11]. Group 1: Research Background - The study was published in the journal Cell on June 30, 2025, by teams from Cincinnati Children's Hospital and UCLA, marking a significant advancement in organoid research [1]. - Prior to this research, organoids generally lacked organ-specific vascular networks, particularly in endoderm-derived organs like the lung and gut, which limited their application in disease modeling and therapeutic contexts [1][2]. Group 2: Methodology and Findings - The research established an in vitro vascularized organoid platform that accurately replicates the co-development of mesoderm and endoderm lineages, enabling efficient differentiation of endoderm-derived cells into organotypic endothelial and mesenchymal cell populations [11]. - The new method requires fewer factors for organoid development: only one inhibitor (Noggin) for lung organoids and three activators (CHIR99021, FGF4, and VEGFA) for gut organoids, allowing for spontaneous formation of vascular networks [13]. - The resulting vascularized organoids exhibited enhanced cellular diversity, improved three-dimensional structure, and physiological functions, such as tight barriers in lung organoids for gas exchange and high permeability in gut organoids for nutrient absorption [13]. Group 3: Implications for Disease Modeling - The vascularized organoids can be utilized to study abnormal intercellular interactions in various disease contexts, such as ACDMPV, a congenital lung disease caused by FOXF1 gene mutations [14]. - By differentiating patient-derived iPSCs with FOXF1 mutations into vascularized lung organoids, the study successfully replicated primary endothelial defects and secondary epithelial abnormalities associated with the disease [14]. - This platform allows for the simultaneous modeling of multi-organ interactions in diseases, providing insights into complex conditions that traditional models could not address [14][15].

Core Viewpoint - The article discusses a novel therapeutic approach targeting pathogenic T cells in autoimmune diseases, focusing on the mechanism of LAG-3 and T Cell Receptor (TCR) interaction, which offers a new strategy for treatment [4][10]. Group 1: Mechanism of Action - Autoimmune diseases are caused by overactive immune responses leading to tissue damage, with T cells playing a crucial role in diseases like type 1 diabetes and rheumatoid arthritis [2][3]. - LAG-3, an inhibitory immune checkpoint receptor, is regulated by its classical ligand MHC-II, and its activation is dependent on the spatial proximity to TCR, which is essential for effective suppression of CD4+ T cells [4][5][7]. - The study reveals that LAG-3's optimal function requires not just interaction with MHC-II but also the formation of a spatial proximity with TCR, which is a key molecular mechanism for T cell inhibition [7][8]. Group 2: Therapeutic Development - The research team developed a bispecific T cell silencer (BiTS) that targets the interaction between LAG-3 and TCR, allowing for selective modulation of pathogenic T cells while preserving beneficial T cell functions [5][10]. - This innovative approach has shown significant therapeutic effects in various animal models of autoimmune diseases, indicating its potential for treating conditions like refractory multiple sclerosis and rheumatoid arthritis [5][10]. - The study provides a unique opportunity for precise intervention in T cell-driven autoimmune diseases, addressing the current lack of safe and effective therapies [10].

脑卒中 （俗称"中风"，包括脑梗塞及脑出血） 作为全球造成残疾和社会负担排名首位的神经系统疾病，平均 约 50% 的幸存者在经过现有治疗和复健后，自我代偿和复健等治疗能带来的功能改善会达到极限，并在 6 个月以后进入稳定期，甚至终身伴随偏瘫、语言功能障碍等后遗症。 最新报告显示， 我国 包括缺血性脑卒中 （脑梗塞） 和脑出血在内的脑卒中患者高达 2800 万 人，每年 新 增 病例约 394 万 。 全球 现有偏瘫患者高达 1 亿 人，每年 新增 约 1500 万 人，其中约 67% 为 70 岁以 下人群，22% 甚至发生在 15-49 岁的青壮年群体，并且这一数字仍然在快速增长和继续年轻化。 目前 全球仅有一款 迷走神经刺激器 （VNS） 结合复健 的治疗手段，平均可改善患者的上肢运动功能评分 （FMA-UE） 约 5.8 分 ，并已作为 突破性 器械疗法在 2021 年被 FDA 批准针对 6 个月以上的稳定偏瘫患 者。由于脑卒中后遗症患者的大量功能神经元死亡和神经环路损伤，而成人脑内神经干细胞的数量和再生能力 有限，通过迷走神经刺激等带来的神经可塑性、传统药物与康复治疗对进入稳定期患者的 功能恢复促进 ...

Core Viewpoint - The study highlights the age-dependent accumulation of mitochondrial tRNA mutations in mouse kidneys, which is linked to mitochondrial kidney diseases, emphasizing the importance of monitoring kidney function in mitochondrial disease patients, especially the elderly [3][4]. Group 1: Research Findings - The research utilized a mitochondrial base editor, DdCBE, to create pathogenic mitochondrial tRNA point mutation mouse models, revealing that these mutations accumulate with age in the kidneys, leading to severe renal defects that mimic human mitochondrial kidney disease [3][6]. - The study identified unique heterogeneity dynamics in different kidney cell types, where podocytes exhibited positive selection for mutated mtDNA, while renal tubular epithelial cells showed neutral drift of mutations during aging [6][7]. - A comprehensive analysis combining mtscATAC-seq, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics (Stereo-seq) determined molecular changes in high mutation-defect cells, including enhanced AP-1 family transcription factor activity, renal tubular epithelial cell proliferation, and immune activation, which promote disease progression [7]. Group 2: Implications for Clinical Practice - The findings underscore the necessity for monitoring kidney function in elderly patients with mitochondrial diseases, establishing a reliable preclinical model to facilitate the development of therapeutic strategies [4].

Core Viewpoint - The article discusses the ambitious vision of creating Artificial Intelligence Virtual Cells (AIVC) to model and predict cellular behavior, leveraging advancements in AI and omics technologies [3][5][7]. Group 1: AI Virtual Cell Development - Multiple research teams are competing to develop AI models for cellular behavior prediction [4]. - The Chan-Zuckerberg Initiative (CZI) plans to invest hundreds of millions over the next decade to create virtual cells [10]. - The development of AI protein structure prediction tools like AlphaFold is contributing to virtual cell projects [10]. Group 2: Current Progress and Challenges - The efforts to create virtual cells are still in the early stages, generating significant interest in academic and industrial labs [8]. - Despite the excitement, some scientists express skepticism about the hype surrounding virtual cells, noting a lack of concrete results and clear success pathways [11]. - Current virtual cell models primarily focus on single-cell RNA sequencing data, which provides snapshots of gene activity and cellular states [16]. Group 3: Data Utilization and Future Directions - CZI plans to release sequencing data from 1 billion cells, while Arc Institute has released data from 100 million cancer cells treated with various drugs [16]. - Researchers are beginning to develop single-cell AI models, with Arc Institute launching its first virtual cell model called "State" [16]. - There is a need for integrating other data forms, such as optical and electron microscopy images, to enhance virtual cell models [17]. Group 4: Definition and Consensus - The concept of virtual cells lacks a clear definition, and there is no consensus among researchers on what constitutes a virtual cell [18]. - Stephen Quake emphasizes that the transition to using virtual cell models in biology will take time, as both the models and the scientists are not yet fully prepared [19].

Core Viewpoint - The study highlights the impact of gut microbiota dysbiosis induced by brain tumors on the efficacy of immunotherapy, suggesting that dietary supplementation with tryptophan can restore gut microbiota and significantly enhance the immune response through T cell circulation [2][11][14]. Group 1: Research Background - The influence of gut microbiota on various tumors, particularly gastrointestinal tumors, is recognized, but its effects on brain tumors remain largely unexplored [2][6]. - Glioblastoma (GBM) is known for its poor prognosis and limited survival rate improvements despite various treatments, attributed to unique characteristics of the tumor microenvironment [4][5]. Group 2: Research Findings - The research utilized a GBM mouse model and employed 16S rRNA sequencing to analyze changes in gut microbiota during tumor progression, finding that tryptophan supplementation could reverse these changes [9]. - Tryptophan supplementation not only restored gut microbiota balance but also significantly improved survival rates in mouse models and enhanced the effectiveness of immunotherapy [9][13]. Group 3: Key Microbial Insights - Among the gut bacteria responding positively to tryptophan, Duncaniella dubosii emerged as a key contributor to the immune modulation effects of tryptophan [10][13]. - The study emphasizes the potential of targeting gut microbiota modulation to improve cancer immunotherapy outcomes, particularly through mechanisms involving T cell regulation [14].